Odyssey Therapeutics’ Post

🎯 BREAKTHROUGH ALERT 🎯 ⚡️ HAPPENING NOW ⚡️ 21st BioPharma Drug Discovery Nexus 👩🔬 SPOTLIGHT ON: Kelly Bachovchin, PhD, Customer Engagement Scientist Collaborative Drug Discovery - CDD Vault. 🔥 DROPPING KNOWLEDGE ON: "Empowering Drug Discovery Research: A Comprehensive Solution for Collaborative AI/ML Workflows" #AIrevolution #DrugDiscovery #ML #Innovation #FuturePharma #CollaborativeAI #DataScience #BioTechInnovation #AIpowered #DrugDevelopment #CloudComputing #MachineLearning #PharmaAI #BioInformatics #RealTimeScience #AIWorkflows #ResearchInnovation #PharmaTech #DataDriven #CollaborativeScience #BioPharmaNexus

🔬 Can AI Accelerate Pharmaceutical Research? VeriSIM Life Thinks So! 💊 VeriSIM Life, based in San Francisco, is revolutionizing drug discovery with its BIOiSIM platform and new AtlasGEN feature. 🌟 🌐 About VeriSIM Life: BIOiSIM uses AI and vast datasets to streamline virtual drug development, cutting costs and reducing animal testing. 🧬 🚀 Introducing Atlasgen: AtlasGEN simulates drug effects in humans and animals, helping researchers pick the best candidates and models. 🐾 🗣 Driven by Passion: CEO Dr. Jo Varshney, with a background in veterinary science and genomics, aims to make drug research more efficient and successful. 💡 📉 Tackling Industry Challenges: VeriSIM Life’s platform can cut the time to FDA approval by 2.5 years and offers 82% greater accuracy in modeling drug effects. 💸 🔍 How It Works: The Translational Index score guides researchers on drug efficacy and the best animal models, ensuring targeted development. 🧪 💬 Join the AI-Driven Healthcare Revolution: VeriSIM Life's AI platform is set to transform drug trials and improve global health. 🌍 👉 Stay Updated: Follow for the latest in AI and healthcare innovations. 🚀 #AI #PharmaceuticalResearch #VeriSIMLife #BIOiSIM #AtlasGEN #HealthcareInnovation #Biotech #Genomics #MachineLearning #ClinicalTrials

🧬💊 A patient's genetic background can influence their response to a drug — an important consideration when designing and testing treatments. Through a collaboration with the European Variation Archive, the Open Targets Platform recently brought in pharmacogenetics data from PharmGKB, adding a new dimension when prioritising targets for drug discovery. In the latest post on our blog, we dive into how we integrated this data, and the new insights it can provide. 👇 Is there other data you want to see in the Platform? Let us know by commenting below!

A highlight of this year’s ON Helix was a wide-ranging panel on ‘New Horizons for BIO Innovation’, all about how to crystallise value from data in a health care setting, and how to protect it. Expertly chaired by Rowan Gardner, it sure packed a lot in, covering cybersecurity, drug repurposing, a new class of drug identified using AI to block cell necrosis, overcoming drug development bottlenecks, and much more. With solid data at its core, it’s time for tech-bio to soar! 🔗Enjoy reading about using Tech-Bio to create value in Bio-Tech, in our write up here: https://lnkd.in/eENPUUAc One Nucleus, PrecisionLife, Rowan Gardner, Naveen Kaushik, Zenzero, Susana Tomasio, Collaborative Drug Discovery - CDD Vault, Dr. Carina Kern, LinkGevity, Nuclera, Cam Watson #biotech #pharma #drugdiscovery #onhelix24 #techbio #lifesciences #drugdevelopment #healthspan #AI

In the captivating tale of "One Thousand and One Nights," Aladdin, a boy of humble origins, finds a magic lamp with a genie ready to grant his wishes. Have you ever wondered what an #antibody might wish for? Chemical Synthesis to bypass cell-based production, ensuring cruelty-free consistency. PCR Amplifiability for unmatched sensitivity in detection. Agility for Allosteric Shifts upon target binding, crucial for dynamic diagnostics. This scenario illustrates aptamers' edge over #antibodies, showcasing their #biotech prowess. Aptamers' #chemical synthesis promises consistent quality without animal use. Their amplifiability and size enable groundbreaking #diagnostic methods, from #proteomics to point-of-care solutions. At NeoVentures, we're not just envisioning this future—we're making it happen. As #aptamerdevelopment pioneers, we aim to revolutionize diagnostics and #therapeutics, empowering people to actively manage their health, with #Neomers at the forefront. Read more on our "One Thousand and One Nights" inspired blog post here: https://lnkd.in/eQBryWMF

Anyone can develop GenAI apps these days, but developing industry changing - and arguably life changing - applications of GenAI is something BCG is uniquely positioned to do. Check out our new partnership with Merck to accelerate and enable drug development. #BCG #BCGX #innovation

AI for Good: ALS drug discovery The Details: ALS, known also as Lou Gehrig’s disease, doesn’t currently have a cure.  Because of this, it has become an area of focus for some biotech and pharmaceutical companies.  Why it matters: “For years, researchers have heavily relied on animal or cell models to identify new targets, in a way that oversimplifies the enormous complexity of human biology, particularly for diseases like ALS,” Dr. Robert H. Scannevin, Verge’s chief scientific officer, said in a statement. “The Converge platform starts with, and integrates, human data and human model systems throughout discovery and development,” providing “unique insights into the biological underpinnings of ALS.” #clinicalresearch #ALS

Orion Corporation Veturi Research Ecosystem Nowadays: Bringing a new drug to the market > 15 years, low success rate. Areas in drug discovery that AI has potential to disrupt: - AI-Driven Target Discovery - right target, right population - AI-Driven Drug Design - right drug for the right target - AI-Driven Clinical Trials - right patients for the right drug Future: By using data & AI optimally in the ecosystem: < 10 years, improved success rate. #research #ecosystem #drugdiscovery #drugdevelopment #bioimaging #biobanking #imageanalysis #machinelearning

Just because it’s faster doesn’t necessarily mean it’ll be more effective. It's important to manage expectations and address challenges such as data quality, ethical considerations, and the need for collaboration between AI experts and domain-specific researchers for successful implementation in the complex field of drug development. #biotechnology #drugdiscovery #drugdevelopment #artificialintelligence

“Driving Drug Discovery Efficiencies in Life Sciences with AI - with Anne Phelan of BenevolentAI” https://lnkd.in/e7gbtpr3 Today’s guest on the ‘AI in Healthcare and Life Sciences’ podcast is Anne Phelan, Chief Scientific Officer at BenevolentAI. BenevolentAI stands at the forefront of AI-enhanced drug discovery, utilizing cutting-edge technology to reveal new biology, identify novel targets, and forge treatments for complex diseases. Anne shares insights into her team's process for developing AI models that predict drug properties, stability, and pharmacological characteristics. This application of AI not only accelerates drug discovery but also increases the precision of these medicinal solutions. Later in the episode, the discussion expands to explore how similar technologies are applied to stratify patient data according to disease traits. This assists in matching the most promising drugs with the right patients, thereby optimizing clinical efficacy. #Healthcare #LifeSciences #AI #DrugDiscovery #BenevolentAI #TechnologyInMedicine #Pharmacology #ClinicalEfficacy #PatientData #DiseaseManagement #InnovationInHealth #ScientificInsight #MedicalResearch #TargetedTherapy #PrecisionMedicine